Latest papers

Clinical trials. Experimental cancer therapies move to the front line.

Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study.

Rank-Minimization with a two-step analysis should replace randomization in clinical trials.

The value of HPV vaccination.

Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.

Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations

More trials are cut short, but not the debate over their trajectory.

["Proven effectiveness studies..." What does concrete actually mean?].

Impact of secondary cardiovascular events on health status.

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis

Ethics and Academic Pediatrics.

Surrogate end points in secondary analyses of cardiovascular trials.

[Current topics for biomarker of testicular cancer].

Should minimization replace randomization in all clinical trials?

Accelerating identification and regulatory approval of investigational cancer drugs.

[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].

New HCV drugs trigger race for more tolerable therapies.

Response burden and questionnaire length: is shorter better? A review and meta-analysis.

Cluster randomised trials.

Long-term safety data support use of bronchial thermoplasty.